A scoping review of cost-effectiveness of screening and treatment for latent tuberculosis infection in migrants from high-incidence countries

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Zammarchi, Lorenzo ^a   Casadei, Gianluigi ^b   Strohmeyer, Marianne ^a   Bartalesi, Filippo ^c   Liendo, Carola ^d   Matteelli, Alberto ^e   Bonati, Maurizio ^b   Gotuzzo, Eduardo ^d   Bartoloni, Alessandro ^a,c   Pandolfini, Chiara ^b   Severino, Francesca ^b   Confalonieri, Valeria ^b   Tognoni, Gianni ^b   Bisoffi, Zeno ^f   Buonfrate, Dora ^f   Angheben, Andrea ^f   Albonico, Marco ^f,g   Muñoz, Jose ^h   Requena Mendez, Ana ^h   Roura, Maria ^h   Ventura, Laia ^h   Pool, Robert ⁱ   Pell, Christopher ⁱ   Hardon, Anita ⁱ   Chiodini, Peter ^j   Moreira, Juan ^k   Anselmi, Mariella ^k   Sempértegui, Roberto ^k   Mena, Maria Alejandra ^d   Garcia, Héctor H ^l   Bustos, Javier ^l   Santivañez, Saul ^l   Torrico, Faustino ^m   Lozano, Daniel ^m   Cabrera, Teresa Hinojosa ⁿ   Morón, Javier Ochoa ⁿ   AbaporiCuellar, Ignacio ⁿ   Suarez, Jaime Amorós ⁿ   ChumirayRojas, Guido ⁿ   Nicoletti, Alessandra ^o   Bruno, Elisa ^o   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^e UNIVERSITY OF BRESCIA   (Italy)

^f Sacro Cuore Don Calabria Hospital   (Italy)

^g Ivo de Carneri Foundation   (Italy)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^k Centre for Community Epidemiology and Tropical Medicine   (Ecuador)

^l UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^m Salud y Medio Ambiente   (Bolivia)

ⁿ Taller de Educacion y Comunicacion TEKO GUARAN   (Bolivia)

^o UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; DENTAL PROCEDURE; ECONOMICS; FEMALE; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIGRATION; TUBERCULIN TEST; TUBERCULOSIS;

COMMUNICABLE DISEASES; COST-BENEFIT ANALYSIS; DENTAL CARE; FEMALE; HUMANS; INCIDENCE; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; TRANSIENTS AND MIGRANTS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84942156014     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-015-1045-3     Document Type: Review

References (35)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. 2012.
2. Klinkenberg E, Manissero D, Semenza JC, Verver S. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J. 2009;34(5):1180-9.
3. Codecasa LR, Porretta AD, Gori A, Franzetti F, Degli Esposti A, Lizioli A, et al. Tuberculosis among immigrants from developing countries in the province of Milan, 1993-1996. Int J Tuberc Lung Dis. 1999;3(7):589-95.
4. Lillebaek T, Andersen AB, Bauer J, Dirksen A, Glismann S, de Haas P, et al. Risk of Mycobacterium tuberculosis transmission in a low-incidence country due to immigration from high-incidence areas. J Clin Microbiol. 2001;39(3):855-61.
5. Diel R, Rusch-Gerdes S, Niemann S. Molecular epidemiology of tuberculosis among immigrants in Hamburg, Germany. J Clin Microbiol. 2004;42(7):2952-60.
6. Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med. 1998;158(6):1871-5.
7. Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialized countries. Emerg Infect Dis. 2012;18(9):1422-9.
8. Franzetti F, Codecasa L, Matteelli A, Degli Esposti A, Bandera A, Lacchini C, et al. Genotyping analyses of tuberculosis transmission among immigrant residents in Italy. Clin Microbiol Infect. 2010;16(8):1149-54.
9. Hernandez-Garduno E, Kunimoto D, Wang L, Rodrigues M, Elwood RK, Black W, et al. Predictors of clustering of tuberculosis in Greater Vancouver: a molecular epidemiologic study. CMAJ. 2002;167(4):349-52.
10. Alvarez GG, Gushulak B, Abu Rumman K, Altpeter E, Chemtob D, Douglas P, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis. 2011;11:3.
11. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2007;11(1):16-26.
12. Broekmans J, Migliori G, Rieder H, Lees J, Ruutu P, Loddenkemper R, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J. 2002;19(4):765-75.
13. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization; 2014. EB134R4.
14. Haycox A, Walley T. Pharmacoeconomics: evaluating the evaluators. Br J Clin Pharmacol. 1997;43:451-6.
15. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis. 2011;11(6):435-44.
16. Pareek M, Bond M, Shorey J, Seneviratne S, Guy M, White P, Lalvani A, Kon OM. Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing:observational study and economic analysis. Thorax. 2013 Mar;68(3):230-9. doi:10.1136/thoraxjnl-2011-201542. Epub 2012.
17. Brassard P, Steensma C, Cadieux L, Lands LC. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics. 2006;117(2):e148-56.
18. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med. 2002;347(23):1850-9.
19. Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med. 2000;162(6):2079-86.
20. Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health. 2006;6:157.
21. Hardy AB, Varma R, Collyns T, Moffitt SJ, Mullarkey C, Watson JP. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax. 2010;65(2):178-80.
22. Iqbal AZ, Leighton J, Anthony J, Knaup RC, Peters EB, Bailey TC. Cost effectiveness of using Quantiferon Gold (QFT-G)(R) versus tuberculin skin test (TST) among U.S. and foreign born populations at a public health department clinic with a low prevalence of tuberculosis. Public Health Nurs (Boston, Mass). 2014;31(2):144-52.
23. Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2011;184(5):590-601.
24. Oxlade O, Pinto M, Trajman A, Menzies D. How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI. PLoS One. 2013;8(3), e56044.
25. Matteelli A, Casalini C, Raviglione MC, El-Hamad I, Scolari C, Bombana E, et al. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. Am J Respir Crit Care Med. 2000;162(5):1653-5.
26. Sterling T, Munsiff SS, Frieden TR. Management of latent tuberculosis infection in immigrants. N Engl J Med. 2003;348(13):1289-92. author reply 1289-1292.
27. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17(12):1531-7.
28. Gagliotti C, Resi D, Moro ML. Delay in the treatment of pulmonary TB in a changing demographic scenario. Int J Tuberc Lung Dis. 2006;10(3):305-9.
29. Mor Z, Kolb H, Lidji M, Migliori G, Leventhal A. Tuberculosis diagnostic delay and therapy outcomes of nonnational migrants in Tel Aviv, 1998-2008. Euro Surveill. 2013;18(12). pii: 20433.
30. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140-56.
31. World Health Organization. Global tuberculosis control 2011. 2011.
32. European Centre for Disease Control and Prevention, World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. In: Surveillance report. Stockholm: European Centre for Disease Control and Prevention; 2012. p. 73-97.
33. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JD. The social determinants of tuberculosis: from evidence to action. Am J Public Health. 2011;101(4):654-62.
34. Rasanathan K, Sivasankara Kurup A, Jaramillo E, Lonnroth K. The social determinants of health: key to global tuberculosis control. Int J Tuberc Lung Dis. 2011;15 Suppl 2:S30-6.
35. Ministero della Salute. Aggiornamento delle raccomandazioni per le attività di controllo della tubercolosi. "Politiche efficaci a contrastare la tubercolosi nella popolazione immigrata". 2010.